<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2023.439</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-1770</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EVENTS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОБЫТИЯ</subject></subj-group></article-categories><title-group><article-title>What has changed over the year in the prevention of venous thromboembolic events in pregnant women and puerperas?</article-title><trans-title-group xml:lang="ru"><trans-title>Что изменилось за год в профилактике венозных тромбоэмболических осложнений у беременных и родильниц?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8404-1042</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бицадзе</surname><given-names>В. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bitsadze</surname><given-names>V. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бицадзе Виктория Омаровна – д.м.н., профессор РАН, профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова </p><p>Scopus Author ID: 6506003478.Researcher ID: F-8409-2017.</p><p>119991 Москва, ул. Большая Пироговская, д. 2, стр. 4</p></bio><bio xml:lang="en"><p>Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health</p><p>Scopus Author ID: 6506003478.Researcher ID: F-84092017</p><p>2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2622-5000</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайнулина</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zainulina</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зайнулина Марина Сабировна – д.м.н., главный врач СПб ГБУЗ «Родильный дом № 6 имени профессора В.Ф. Снегирева»; профессор кафедры акушерства, гинекологии и репродуктологии ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова»</p><p>Scopus Author ID: 37076359000. Researcher ID: B-5746-2018</p><p>192014 Санкт-Петербург, ул. Маяковского, д. 5; 197022 Санкт-Петербург, ул. Льва Толстого, д. 6/8</p></bio><bio xml:lang="en"><p>Marina S. Zainulina – MD, Dr Sci Med, Head Physician, Snegirev Maternity Hospital № 6, Saint Petersburg; Professor, Department of Obstetrics, Gynecology and Reproductive Medicine, Pavlov First Saint Petersburg State Medical University</p><p>Scopus Author ID: 37076359000.Researcher ID: B-5746-2018.</p><p>5 Mayakovskogo Str., Saint Petersburg 192014;6/8 Lev Tolstoy Str., Saint Petersburg 197022</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0725-9686</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хизроева</surname><given-names>Д. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Khizroeva</surname><given-names>J. Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хизроева Джамиля Хизриевна – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова </p><p>Scopus Author ID: 57194547147.Researcher ID: F-8384-2017</p><p>119991 Москва, ул. Большая Пироговская, д. 2, стр. 4</p></bio><bio xml:lang="en"><p>Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health</p><p>Scopus Author ID: 57194547147.Researcher ID: F-8384-2017</p><p>2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9459-5698</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николаева Мария Геннадьевна – д.м.н., профессор кафедры акушерства и гинекологии с курсом дополнительного профессионального образования ФГБОУ ВО «Алтайский государственный медицинский университет» ; старший научный сотрудник, Алтайский филиал ФГБУ «Национальный медицинский исследовательский центр гематологии»</p><p>Scopus Author ID: 57191960907. Researcher ID: AAI-6271-2020.</p><p>656038 Барнаул, пр. Ленина, д. 40; 656045 Барнаул, ул. Ляпидевского, д. 1</p></bio><bio xml:lang="en"><p>Mariya G. Nikolaeva – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology with а Course of Professional Postgraduate Education, Altai State Medical University; Senior Researcher, Altai Branch of National Medical Research Center for Hematology</p><p>Scopus Author ID: 57191960907. Researcher ID: AAI-6271-2020.</p><p>40 Lenin Avе., Barnaul 656038; 1 Lyapidevskogo Str., Barnaul 656045</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7415-4633</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макацария</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Makatsariya</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макацария Александр Давидович – д.м.н., профессор, академик РАН, зав. кафедрой акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова  Сеченовского Университета; вице-президент Российского общества акушеров-гинекологов (РОАГ); Заслуженный врач Российской Федерации; Почетный профессор Венского Университета</p><p>Scopus Author ID: 57222220144.Researcher ID: M-5660-2016</p><p>119991 Москва, ул. Большая Пироговская, д. 2, стр. 4</p></bio><bio xml:lang="en"><p>Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health, Sechenov University; Vice-President of the Russian Society of Obstetricians and Gynecologists (RSOG); Honorary Doctor of the Russian Federation; Emeritus Professor of the University of Vienna</p><p>2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>СПб ГБУЗ «Родильный дом № 6 имени профессора В.Ф. Снегирева; &#13;
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Snegirev Maternity Hospital № 6; &#13;
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Алтайский государственный медицинский университет» Министерства здравоохранения Российской Федерации; &#13;
Алтайский филиал ФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Altai State Medical University, Health Ministry of Russian Federation; &#13;
Altay Branch of National Medical Research Center for Hematology, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>06</day><month>09</month><year>2023</year></pub-date><volume>17</volume><issue>4</issue><fpage>533</fpage><lpage>545</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Bitsadze V.O., Zainulina M.S., Khizroeva J.K., Nikolaeva M.G., Makatsariya A.D., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бицадзе В.О., Зайнулина М.С., Хизроева Д.Х., Николаева М.Г., Макацария А.Д.</copyright-holder><copyright-holder xml:lang="en">Bitsadze V.O., Zainulina M.S., Khizroeva J.K., Nikolaeva M.G., Makatsariya A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/1770">https://www.gynecology.su/jour/article/view/1770</self-uri><abstract><p>An issue of venous thromboembolic events (VTEs) in pregnant women and puerperas in Russia as well as throughout the world remains relevant. Specialized events with expert’s participation could not be better to promote active discussion and constructive solution of complex problems, which refer to issues of VTEs prevention. Indeed, not disputable issues can be solved, but critical look and reasoned opinion leader presentations in the field undoubtedly improve our understanding and approaches to prevention of threatening complications in pregnant women and puerperas such as VTEs. In addition, actively discussed new data for dosing of low molecular weight heparins (LMWH) in pregnant women will allow to update current clinical guidelines, which would probably improve clinical outcomes of therapy.</p></abstract><trans-abstract xml:lang="ru"><p>В России, как и во всем мире, проблема венозных тромбоэмболических осложнений (ВТЭО) у беременных и родильниц не теряет актуальности. Специализированные мероприятия с участием экспертов как нельзя лучше способствуют активному обсуждению и конструктивному решению сложных задач, к которым относится тромбопрофилактика в акушерстве. Безусловно, не на все спорные вопросы имеются ответы, но критический взгляд и аргументированные выступления лидеров мнения по рассматриваемому направлению, несомненно, улучшат понимание и подходы к вопросу профилактики грозных осложнений у беременных и рожениц, каковыми являются тромбоэмболические события. К тому же активно обсуждаемые новые данные по дозированию низкомолекулярных гепаринов (НМГ) у беременных позволят обновить текущие клинические рекомендации, что, вероятно, улучшит клинические исходы терапии.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>венозные тромбоэмболические осложнения</kwd><kwd>ВТЭО</kwd><kwd>клинические рекомендации</kwd><kwd>низкомолекулярные гепарины</kwd><kwd>НМГ</kwd><kwd>фраксипарин</kwd><kwd>дозы</kwd><kwd>биоаналоги</kwd></kwd-group><kwd-group xml:lang="en"><kwd>venous thromboembolic events</kwd><kwd>VTEs</kwd><kwd>low molecular weight heparins</kwd><kwd>LMWHs</kwd><kwd>Fraxiparine</kwd><kwd>dosage</kwd><kwd>biosimilars</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Surveillance of maternal deaths in the UK 2011-13 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-13. MBRRACE-UK, 2015. 116 р. Available at: https://maternalmentalhealthalliance.org/wp-content/uploads/MBRRACE-UK-Maternal-Report-2015-3.pdf.</mixed-citation><mixed-citation xml:lang="en">Surveillance of maternal deaths in the UK 2011-13 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-13. MBRRACE-UK, 2015. 116 р. Available at: https://maternalmentalhealthalliance.org/wp-content/uploads/MBRRACE-UK-Maternal-Report-2015-3.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Здравоохранение в России. Статистический сборник. М.: Федеральная служба государственной статистики (Росстат), 2019. 171 с. Режим доступа: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf.</mixed-citation><mixed-citation xml:lang="en">Health care in Russia. Statistical compendium. [Zdravoohranenie v Rossii. Statisticheskij sbornik]. Moscow: Federal'naya sluzhba gosudarstvennoj statistiki (Rosstat), 2019. 171 p. (In Russ.). Available at: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gris J.-C., Aoun J., Rzaguliyeva L. et al. Risk assessment and management of venous thromboembolism in women during pregnancy and puerperium (SAVE): an international, cross-sectional study. TH Open. 2018;2(2):e116–e130. https://doi.org/10.1055/s-0038-1635573.</mixed-citation><mixed-citation xml:lang="en">Gris J.-C., Aoun J., Rzaguliyeva L. et al. Risk assessment and management of venous thromboembolism in women during pregnancy and puerperium (SAVE): an international, cross-sectional study. TH Open. 2018;2(2):e116–e130. https://doi.org/10.1055/s-0038-1635573.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson F.A., Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):9–16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6.</mixed-citation><mixed-citation xml:lang="en">Anderson F.A., Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):9–16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: RCOG, 2015. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines.</mixed-citation><mixed-citation xml:lang="en">Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: RCOG, 2015. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации – Венозные осложнения во время беременности и послеродовом периоде. Акушерская тромбоэмболия – 2022-2023-2024 (14.02.2022). М.: Министерство здравоохранения Российской Федерации, 2022. 66 с. Режим доступа: http://disuria.ru/_ld/11/1153_kr22O22MZ.pdf.</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines – Venous complications during pregnancy and the postpartum period. Obstetric thromboembolism – 2022-2023-2024 (14.02.2022). [Klinicheskie rekomendacii – Venoznye oslozhneniya vo vremya beremennosti i poslerodovom periode. Akusherskaya tromboemboliya – 2022-2023-2024 (14.02.2022)]. Moscow: Health Ministry of Russian Federation, 2022. 66 p. (In Russ.). Available at: http://disuria.ru/_ld/11/1153_kr22O22MZ.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный закон РФ от 29.11.2010 N 326-ФЗ – Об обязательном медицинском страховании в РФ – Действующая последняя редакция от 24.02.2021 – Редакция N 35 – В действии с 24.02.2021. 87 c. Режим доступа: http://disuria.ru/_ld/0/62_326FZ29112010.pdf.</mixed-citation><mixed-citation xml:lang="en">Federal Law of the Russian Federation of November 29, 2010 N 326-FZ – On Compulsory Medical Insurance in the Russian Federation – The latest version in force of February 24, 2021 – Edition N 35 – In force from February 24, 2021. [Federal'nyj zakon RF ot 29.11.2010 N 326-FZ – Ob obyazatel'nom medicinskom strahovanii v RF – Dejstvuyushchaya poslednyaya redakciya ot 24.02.2021 – Redakciya N 35 – V dejstvii s 24.02.2021]. 87 c. (In Russ.). Available at: http://disuria.ru/_ld/0/62_326FZ29112010.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Greer I.A., Nelson-Piercy С. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. https://doi.org/10.1182/blood-2005-02-0626.</mixed-citation><mixed-citation xml:lang="en">Greer I.A., Nelson-Piercy С. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. https://doi.org/10.1182/blood-2005-02-0626.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Simeone R., Giacomello R., Bruno G. et al. Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight heparin prophylaxis. Acta Haematol. 2017;137(4):201–6. https://doi.org/10.1159/000467385.</mixed-citation><mixed-citation xml:lang="en">Simeone R., Giacomello R., Bruno G. et al. Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight heparin prophylaxis. Acta Haematol. 2017;137(4):201–6. https://doi.org/10.1159/000467385.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):e18–e34. https://doi.org/10.1097/AOG.0000000000002703.</mixed-citation><mixed-citation xml:lang="en">ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):e18–e34. https://doi.org/10.1097/ AOG.0000000000002703.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.</mixed-citation><mixed-citation xml:lang="en">Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Henriksson P., Westerlund E., Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.</mixed-citation><mixed-citation xml:lang="en">Henriksson P., Westerlund E., Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.</mixed-citation><mixed-citation xml:lang="en">Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Olausson N., Discacciati A., Nyman A.I. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.</mixed-citation><mixed-citation xml:lang="en">Olausson N., Discacciati A., Nyman A.I. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Arya R., Shehata H.A., Patel R.K. et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol. 2001;115(1):153–5. https://doi.org/10.1046/j.1365-2141.2001.03081.x.</mixed-citation><mixed-citation xml:lang="en">Arya R., Shehata H.A., Patel R.K. et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol. 2001;115(1):153–5. https://doi.org/10.1046/j.1365-2141.2001.03081.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rova K., Henrik Passmark H., Lindqvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.</mixed-citation><mixed-citation xml:lang="en">Rova K., Henrik Passmark H., Lindqvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.</mixed-citation><mixed-citation xml:lang="en">Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">van Lennep J.E.R., Meijer E., Klumper F.J.C.M et al. Low-molecularweight-heparin and pregnancy, when the dose does it: a nephrologist’s opinion: reply to a rebuttal. J Thromb Haemost. 2011;9(10):2129–30. https://doi.org/10.1111/j.1538-7836.2011.04441.x.</mixed-citation><mixed-citation xml:lang="en">van Lennep J.E.R., Meijer E., Klumper F.J.C.M et al. Low-molecularweight-heparin and pregnancy, when the dose does it: a nephrologist’s opinion: reply to a rebuttal. J Thromb Haemost. 2011;9(10):2129–30. https://doi.org/10.1111/j.1538-7836.2011.04441.x.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bleker S.M., Buchmüller A., Chauleur C. et al. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. Thromb Res. 2016;144:62–6. https://doi.org/10.1016/j.thromres.2016.06.001.</mixed-citation><mixed-citation xml:lang="en">Bleker S.M., Buchmüller A., Chauleur C. et al. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. Thromb Res. 2016;144:62–6. https://doi.org/10.1016/j.thromres.2016.06.001.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bistervels I.M., Buchmüller A., Wiegers H.M.G. et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;400(10365):1777–87. https://doi.org/10.1016/S0140-6736(22)02128-6.</mixed-citation><mixed-citation xml:lang="en">Bistervels I.M., Buchmüller A., Wiegers H.M.G. et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;400(10365):1777–87. https://doi.org/10.1016/S0140-6736(22)02128-6.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Шмаков Р.Г., Вавилова Т.В, Николаева М.Г. и др. Краткие алгоритмы диагностики, профилактики и лечения венозных тромбоэмболических осложнений во время беременности. Акушерство и гинекология. 2022;12 (приложение):4–12.</mixed-citation><mixed-citation xml:lang="en">Shmakov R.G., Vavilova T.V., Nikolaeva M.G. et al. Brief algorithms for the diagnosis, prevention and treatment of venous thromboembolic complications during pregnancy. [Kratkie algoritmy diagnostiki, profilaktiki i lecheniya venoznyh tromboembolicheskih oslozhnenij vo vremya beremennosti]. Akusherstvo i ginekologiya. 2022;12 (prilozhenie):4–12. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">van der Wall S.J., Klok F.A., den Exter P.L. et al. Higher adherence to treatment with low-molecular-weight-heparin Nadroparin than Enoxaparin because of side effects in cancer-associated venous thromboembolism. Hemasphere. 2018;2(1):e19. https://doi.org/10.1097/HS9.0000000000000019.</mixed-citation><mixed-citation xml:lang="en">van der Wall S.J., Klok F.A., den Exter P.L. et al. Higher adherence to treatment with low-molecular-weight-heparin Nadroparin than Enoxaparin because of side effects in cancer-associated venous thromboembolism. Hemasphere. 2018;2(1):e19. https://doi.org/10.1097/HS9.0000000000000019.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88(7):913–30. https://doi.org/10.1046/j.0007-1323.2001.01800.x</mixed-citation><mixed-citation xml:lang="en">Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88(7):913–30. https://doi.org/10.1046/j.0007-1323.2001.01800.x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Snijder C.A., Cornette J.M.W., Hop W.C.J. et al. Thrombophylaxis and bleeding complications after cesarean section. Acta Obstet Gynecol Scand. 2012;91(5):560–56. https://doi.org/10.1111/j.1600-0412.2012.01351.x.</mixed-citation><mixed-citation xml:lang="en">Snijder C.A., Cornette J.M.W., Hop W.C.J. et al. Thrombophylaxis and bleeding complications after cesarean section. Acta Obstet Gynecol Scand. 2012;91(5):560–56. https://doi.org/10.1111/j.1600-0412.2012.01351.x.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Бицадзе В.О., Слуханчук Е.В., Хизроева Д.Х. и др. Антикоагулянтные, противовоспалительные, противовирусные и противоопухолевые свойства гепаринов. Акушерство, Гинекология и Репродукция. 2021;15(3):295–312. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.216.</mixed-citation><mixed-citation xml:lang="en">Bitsadze V.O., Slukhanchuk E.V., Khizroeva J.K. et al. Anticoagulant, antiinflammatory, antiviral and antitumor properties of heparins. [Antikoagulyantnye, protivovospalitel'nye, protivovirusnye i protivoopuholevye svojstva geparinov]. Obstetrics, Gynecology and Reproduction. 2021;15(3):295–312. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.216.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:296–329. https://doi.org/10.1161/CIRCULATIONAHA.107.188209.</mixed-citation><mixed-citation xml:lang="en">Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:296–329. https://doi.org/10.1161/CIRCULATIONAHA.107.188209.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hirsh J., Bauer K.A., Donati M.B. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–159S. https://doi.org/10.1378/chest.08-0689.</mixed-citation><mixed-citation xml:lang="en">Hirsh J., Bauer K.A., Donati M.B. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–159S. https://doi.org/10.1378/chest.08-0689.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fareed J., Walenga J.M., Hoppensteadt D. et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989;556:333–53. https://doi.org/10.1111/j.1749-6632.1989.tb22515.x.</mixed-citation><mixed-citation xml:lang="en">Fareed J., Walenga J.M., Hoppensteadt D. et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989;556:333–53. https://doi.org/10.1111/j.1749-6632.1989. tb22515.x.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ofosu F.A. Differences in the safety profiles of two low-molecular-weight heparins. Thromb Haemost. 2008;99(6):989–90. https://doi.org/10.1160/TH08-05-0274.</mixed-citation><mixed-citation xml:lang="en">Ofosu F.A. Differences in the safety profiles of two low-molecular-weight heparins. Thromb Haemost. 2008;99(6):989–90. https://doi.org/10.1160/TH08-05-0274.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Nenci G.G. Low molecular weight heparins: are they interchangeable? No.J Thromb Haemost. 2003;1:12–3.</mixed-citation><mixed-citation xml:lang="en">Nenci G.G. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost. 2003;1:12–3.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">van der Heijden J.F., Prins M.H., Büller H.R. Low molecular weight heparins: are they interchangeable? Haemostasis. 2000;30 Suppl 2:148– 57. https://doi.org/10.1159/000054183.</mixed-citation><mixed-citation xml:lang="en">van der Heijden J.F., Prins M.H., Büller H.R. Low molecular weight heparins: are they interchangeable? Haemostasis. 2000;30 Suppl 2:148– 57. https://doi.org/10.1159/000054183.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kistler U., Kramers-de Quervain I., Munzinger U., Kucher N. Bleeding complications after systemic switch of routine prophylaxis for major orthopedic surgery. Thromb Haemost. 2008;99(6):1049–52. https://doi.org/10.1160/TH08-01-0019.</mixed-citation><mixed-citation xml:lang="en">Kistler U., Kramers-de Quervain I., Munzinger U., Kucher N. Bleeding complications after systemic switch of routine prophylaxis for major orthopedic surgery. Thromb Haemost. 2008;99(6):1049–52. https://doi.org/10.1160/TH08-01-0019.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Maddineni J., Walenga J.M., Jeske W.P. et al. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006;12(3):267–76. https://doi.org/10.1177/1076029606291434.</mixed-citation><mixed-citation xml:lang="en">Maddineni J., Walenga J.M., Jeske W.P. et al. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006;12(3):267–76. https://doi.org/10.1177/1076029606291434.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Identifies Tainted Heparin in 11 Countries. The New York Times. April 22, 2008. Available at: https://www.nytimes.com/2008/04/22/health/policy/22fda.html.</mixed-citation><mixed-citation xml:lang="en">U.S. Identifies Tainted Heparin in 11 Countries. The New York Times. April 22, 2008. Available at: https://www.nytimes.com/2008/04/22/health/policy/22fda.html.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Stevenson J.G. Clinical Data and Regulatory Issues of Biosimilar Products. Am J Manag Care. 2016;21(16 Suppl):s320–s330.</mixed-citation><mixed-citation xml:lang="en">Stevenson J.G. Clinical Data and Regulatory Issues of Biosimilar Products. Am J Manag Care. 2016;21(16 Suppl):s320–s330.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gray E., Rigsby P., Behr-Gross M.-E. Collaborative study to establish the low-molecular-mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004;2004(1):59–76.</mixed-citation><mixed-citation xml:lang="en">Gray E., Rigsby P., Behr-Gross M.-E. Collaborative study to establish the low-molecular-mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004;2004(1):59–76.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Harenberg J., Kakkar A., Bergqvist D. et al.; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost. 2009;7(7):1222–5. https://doi.org/10.1111/j.1538-7836.2009.03349.x.</mixed-citation><mixed-citation xml:lang="en">Harenberg J., Kakkar A., Bergqvist D. et al.; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost. 2009;7(7):1222–5. https://doi.org/10.1111/j.1538-7836.2009.03349.x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
